source
- Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisitionNovo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
- Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidatesCavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…